Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
Standard
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. / Pfisterer, Jacobus; Du Bois, Andreas; Bentz, Eva-Katrin; Kommoss, Friedrich; Harter, Philipp; Huober, Jens; Schmalfeldt, Barbara; Burchardi, Nicole; Arnold, Norbert; Hilpert, Felix.
In: INT J GYNECOL CANCER, Vol. 19, No. 1, 01.2009, p. 109-15.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
AU - Pfisterer, Jacobus
AU - Du Bois, Andreas
AU - Bentz, Eva-Katrin
AU - Kommoss, Friedrich
AU - Harter, Philipp
AU - Huober, Jens
AU - Schmalfeldt, Barbara
AU - Burchardi, Nicole
AU - Arnold, Norbert
AU - Hilpert, Felix
PY - 2009/1
Y1 - 2009/1
N2 - OBJECTIVES: Results on the prognostic value of human epidermal growth factor receptor 2 (HER-2)/neu in ovarian cancer are inconsistent. This exploratory analysis evaluates Her-2/neu as a prognostic factor in a large cohort of patients with advanced-stage ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy within a prospective randomized trial.METHODS: Her-2/neu expression was assessed by immunohistochemistry in 359 patients (46%) treated within the AGO-OVAR 3 trial (n = 783). Patients received either cisplatin/paclitaxel or carboplatin/paclitaxel according to the study protocol. Immunohistochemistry results were scored according to the Dako score.RESULTS: Her-2/neu Dako scores of 0 or 1+ was found in 337 patients (94%) and a score of 2+ or 3+ in 22 patients (6%). Her-2/neu overexpression (2+/3+) was associated with a higher International Federation of Gynecology and Obstetrics stage and larger postoperative residual disease. There were no significant differences in response to chemotherapy between the Her-2/neu score subgroups and in progression-free survival time. In a multivariate analysis, the Her-2/neu score had no significant impact on overall survival time.CONCLUSIONS: In the present study, Her-2/neu overexpression in patients with advanced-stage ovarian cancer was rare and provided no evidence for a prognostic value of Her-2/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel.
AB - OBJECTIVES: Results on the prognostic value of human epidermal growth factor receptor 2 (HER-2)/neu in ovarian cancer are inconsistent. This exploratory analysis evaluates Her-2/neu as a prognostic factor in a large cohort of patients with advanced-stage ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy within a prospective randomized trial.METHODS: Her-2/neu expression was assessed by immunohistochemistry in 359 patients (46%) treated within the AGO-OVAR 3 trial (n = 783). Patients received either cisplatin/paclitaxel or carboplatin/paclitaxel according to the study protocol. Immunohistochemistry results were scored according to the Dako score.RESULTS: Her-2/neu Dako scores of 0 or 1+ was found in 337 patients (94%) and a score of 2+ or 3+ in 22 patients (6%). Her-2/neu overexpression (2+/3+) was associated with a higher International Federation of Gynecology and Obstetrics stage and larger postoperative residual disease. There were no significant differences in response to chemotherapy between the Her-2/neu score subgroups and in progression-free survival time. In a multivariate analysis, the Her-2/neu score had no significant impact on overall survival time.CONCLUSIONS: In the present study, Her-2/neu overexpression in patients with advanced-stage ovarian cancer was rare and provided no evidence for a prognostic value of Her-2/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel.
KW - Aged
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Carboplatin
KW - Cisplatin
KW - Female
KW - Genes, erbB-2
KW - Humans
KW - Middle Aged
KW - Ovarian Neoplasms
KW - Paclitaxel
KW - Predictive Value of Tests
KW - Prognosis
KW - Prospective Studies
KW - Tumor Markers, Biological
U2 - 10.1111/IGC.0b013e3181991a7c
DO - 10.1111/IGC.0b013e3181991a7c
M3 - SCORING: Journal article
C2 - 19258951
VL - 19
SP - 109
EP - 115
JO - INT J GYNECOL CANCER
JF - INT J GYNECOL CANCER
SN - 1048-891X
IS - 1
ER -
